HLA-I与KIR配体受体交互与1型糖尿病进展的关联分析
本研究对DPT-1和TN07试验中1215名已血清转化参与者进行HLA-I和KIR基因测序,用Cox模型分析配体受体交互(LRI)与1型糖尿病从1/2期进展至3期的关联。发现个别LRI与进展相关,如A*03:01-KIR2DS4携带者进展较慢(HR 0.36),B*07:02-KIR2DL3携带者亦较慢(HR 0.26),提示LRI而非单基因影响疾病进展。
要点
- KIR和HLA-I单基因与1型糖尿病进展无或仅零星关联。
- A*03:01-KIR2DS4携带者进展较慢(HR 0.36,p=3.06×10⁻²)。
- B*07:02-KIR2DL3携带者进展较慢(HR 0.26,p=7.76×10⁻³)。
核心结论
- KIR-HLA-I配体受体交互而非单个基因贡献于1型糖尿病进展。
- 此类交互可能通过静电和范德华力稳定,涉及HLA-I抗原结合槽C端,提示新机制。
研究设计与样本
- 对DPT-1和TN07试验中1215名已血清转化参与者进行HLA-I和KIR基因二代测序。
- 采用Cox回归模型系统探索HLA-I-KIR配体受体交互与疾病进展的关联。
- 通过同源建模研究已鉴定LRI复合物的结构特性。
主要发现
- KIR和HLA-I基因与疾病进展无或仅零星关联。
- 所有可能LRI中,9个HLA-A配体和14个HLA-B配体与相应受体对进展有适度关联(p<0.05)。
- A*03:01-KIR2DS4携带者进展较慢(HR 0.36,p=3.06×10⁻²)。
- B*07:02-KIR2DL3携带者进展较慢(HR 0.26,p=7.76×10⁻³)。
- 结构研究表明蛋白序列编码的静电和范德华交互产生强生物物理LRI,可能改变1型糖尿病进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this work was to explore associations between type 1 diabetes progression from stages 1 or 2 to stage 3 and interacting ligand-receptor complexes of HLA class I (HLA-I) and KIR gene products. METHODS: Applying next-generation sequencing technology to genotype HLA-I genes (HLA-A, -B, -C) and KIR genes (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL3, KIR3DS1, KIR2DP1, KIR3DP1) from 1215 participants in the Diabetes Prevention Trial-Type 1 (DPT-1) and the Diabetes Prevention Trial (TN07), we systematically explored associations of HLA-I-KIR ligand-receptor interactions (LRIs) with disease progression via a Cox regression model. We investigated the structural properties of identified LRI complexes. RESULTS: KIR and HLA-I genes had no or sporadic associations with disease progression. Out of all possible LRIs, nine HLA-A Ligands and 14 HLA-B ligands with corresponding receptors had modest associations with progression (p<0.05). As an example, carriers of A*03:01-KIR2DS4 had slower progression (HR 0.36, p=3.06 × 10-2), as did B*07:02-KIR2DL3 carriers (HR 0.26, p=7.76 × 10-3). Structural investigations of KIR-HLA-I complexes via homology modelling based on already-solved respective complex structures suggested that the respective electrostatic and van der Waals interactions encoded in the protein sequences result in strong biophysical LRIs, which could alter the progression of type 1 diabetes. CONCLUSIONS/INTERPRETATION: These results reveal that LRIs of KIR-HLA-I gene products, rather than individual genes, contribute to type 1 diabetes progression, and such interactions are likely to be stabilised by electrostatic and van der Waals forces. As the KIR-HLA-I interactions involve part of the C-terminus of the antigen-binding groove of HLA-I, but may be affected by the respective bound peptide, this suggests a new mechanism for type 1 diabetes pathogenesis. DATA AVAILABILITY: Clinical data on participants in DPT-1 and TN07 can be obtained from the NIDDK-Central Repository ( https://repository.niddk.nih.gov/home ) following the formal approval process.
引用
- Zhao LP, Papadopoulos GK, McFarland BJ, et al. Profiling associations of interactive ligand-receptors (HLA class I and KIR gene products) with the progression to type 1 diabetes among seroconverted participants. Diabetologia. 2025. PMID: 40835749. doi:10.1007/s00125-025-06520-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。